We bring you the latest news from the healthcare about the health care in the United Kingdom. Do your have news for us? Contact the editor. Watch also this special movie.

zaterdag 21 oktober 2017

The Lancet: [Articles] Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men...

[Articles] Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic evaluation
This analysis suggests that the introduction of a PrEP programme for MSM in the UK is cost-effective and possibly cost-saving in the long term. A reduction in the cost of antiretroviral drugs (including the drugs used for PrEP) would substantially shorten the time for cost savings to be realised.
Read more

[Comment] Pre-exposure prophylaxis is cost-effective for HIV in the UK
At the International AIDS Society (IAS) conference in Paris, France, in July, 2017, new data were presented showing a large reduction in HIV diagnoses in the UK's largest sexual health clinic. 56 Dean Street in Soho (London, UK) saw a 42% drop in new diagnoses between 2015 and 2016.1,2 Similarly promising findings were reported in studies of clinics in France and Australia. This reduction is likely to be due to increased testing, earlier diagnosis, and immediate initiation onto HIV treatment at diagnosis,3 as well as increased availability of pre-exposure prophylaxis (PrEP) for HIV.
Read more

[Articles] A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial
The new TdaP(PTgen/FHA) vaccine is safe and induces higher pertussis responses 28 days after vaccination than does the available licensed Tdap booster vaccine. Results of our trial led to the licensure of new acellular pertussis vaccines containing genetically inactivated pertussis toxin in Thailand. The availability of recombinant monovalent pertussis vaccines that induce high antibody responses provides the medical community and consumers with the opportunity to vaccinate against pertussis when immunisation against diphtheria and tetanus is not required or not desired.
Read more

[Corrections] Corrections
Weber WP, Mujagic E, Zwahlen M. Timing of surgical antimicrobial prophylaxis: a phase 3 randomised controlled trial. Lancet Infect Dis 2017; published online April 3. http://dx.doi.org/10.1016/S1473-3099(17)30176-7—Urs von Holzen was missing from the author list of this Article. This correction has been made to the online version as of Oct 20, 2017
Read more

[Comment] Acellular pertussis vaccines: where to go to?
Since their introduction in the 1940s and 1950s, pertussis vaccines (mostly in combination with diphtheria and tetanus toxoids as diphtheria, tetanus, and pertussis vaccines) have been very efficient in reducing pertussis mortality and morbidity in infants and young children. WHO estimates suggest that between 1999 and 2014, more than 100 000 infant deaths could have been averted mainly by increased coverage of pertussis vaccination.1 Pertussis vaccines come in two varieties: one is made of whole-cell killed Bordetella pertussis cells, consequently called whole-cell pertussis vaccine, and the other is made from one to five purified and partly chemically inactivated bacterial virulence factors, consequently called acellular pertussis vaccine.
Read more